A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Latest Information Update: 17 Jan 2026
At a glance
- Drugs Docetaxel (Primary) ; Nelmastobart (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors STCube Pharmaceuticals
Most Recent Events
- 02 Jan 2026 New trial record